choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:

Celebrex Newsletter
  • Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development 22 Oct 2025 12:00 GMT

    … and holds a Doctor of Veterinary Medicine from University of … of experience in pharmaceutical development, including drugs, biologics, medical devices, and … biotechnology company dedicated to the discovery and global development of novel treatments

  • People’s Pharmacy: Pain-relieving drug Journavx not yet approved for chronic pain 12 Oct 2025 13:15 GMT

    … acetaminophen) or an NSAID like Celebrex when I’m on it … help! A. The pain-relieving drug Journavx (suzetrigine) was approved … to be your problem. Doctors can prescribe Journavx for trauma … pain. The FDA does not regulate the practice of medicine, though. So …

  • 维泰瑞隆宣布关键管理层任命,助力推动全球药物研发进程 22 Oct 2025 12:00 GMT

    … NDA/BLA)的批准,涵盖多个治疗领域,包括著名药物西乐葆® (Celebrex®)、爱博新® (Ibrance®)和新冠疫苗Comirnaty®。他的经验涉及小分子、生物制剂、抗体偶联药物(ADC)、基因治疗以及疫苗等多种药物类型。加入维泰瑞隆之前,他曾担任辉瑞公司的首席非临床安全官,全面负责公司全球药物和疫苗产品组合的非临床安全工作。 … 博士在Catalyst Pharmaceuticals担任首席医学和药政官。在此之前,他曾于勃林格殷格翰等多家知名企业担任高级管理职位。 Gary …

  • 維泰瑞隆宣佈關鍵管理層任命,助力推動全球藥物研發進程 22 Oct 2025 12:00 GMT

    … NDA/BLA)的批准,涵蓋多個治療領域,包括著名藥物痛博士®(Celebrex®)、愛博新®(Ibrance®)和新冠疫苗Comirnaty®。他的經驗涉及小分子、生物製劑、抗體偶聯藥物(ADC)、基因治療以及疫苗等多種藥物類型。加入維泰瑞隆之前,他曾擔任輝瑞公司的首席非臨床安全官,全面負責公司全球藥物和疫苗產品組合的非臨床安全工作。 … Ingenito博士在Catalyst Pharmaceuticals擔任首席醫學和藥政官。在此之前,他曾於勃林格殷格翰等多家知名企業擔任高級管理職位。 Gary …

  • LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani 25 Sep 2025 12:30 GMT

    … 2 clinical trial for bipolar depression. LB Pharmaceuticals is building … of two important clinical trials early next year,” said … safer, more effective neuropsychiatric treatments to patients.” Mr. Kane … including Zoloft, Zyrtec and Celebrex. He holds an MBA …

  • Acupotomy for Military Training-Induced Lumbar Radiculopathy with Sciatica: Protocol of a Randomized Controlled Trial 16 Aug 2025 07:10 GMT

    … during the trial, (5) taking drugs that have … regulated intervention methods. Celebrex (Pfizer Pharmaceutical) may be prescribed … the military. Study doctors will make the diagnoses … pivotal non-pharmacological military medicine treatment, reducing reliance on …

  • 13 Drugs and Supplements That Make Your Skin More Sensitive to the Sun 21 Jul 2025 20:02 GMT

    … beds. Some medications or supplements can … trimethoprim) 2. Tricyclic Antidepressants Tricyclic antidepressants, such as the … Statins Statins, which are a type of cholesterol-lowering drug, … include: Aleve (naproxen) Celebrex (celecoxib) Feldene (piroxicam) …

  • Zydus' Non-Steroidal Painkiller Receives FDA Final Nod 15 Jul 2025 22:51 GMT

    … that its nonsteroidal anti-inflammatory drug (NSAID), Celecoxib, has … U.S. Food and Drug Administration (FDA). Celecoxib is used … The approved drug is the generic version of Celebrex, originally marketed … of 492 Abbreviated New Drug Applications (ANDAs) since …

  • Some Drugs Can Make You Extra Vulnerable to Sun and Heat 08 Jul 2025 07:57 GMT

    … Cholesterol-Lowering Drugs Some prescription drugs used to lower … ) naproxen (Aleve) celecoxib (Celebrex) piroxicam (Feldene) ketoprofen (Orudis … , she says. These medications include: acitretin (Soriatane) … sulfonylureas, a diabetes treatment that can make …

  • ABC’s covert promotion of killer drug REMDESIVIR in TV show sparks legal firestorm 07 Jul 2025 14:12 GMT

    pharmaceutical products like remdesivir and Paxlovid through the fictional medical drama "Doctor … failure rates, while allegedly omitting FDA-mandated disclaimers. A demand letter … ;s COVID drug of choice KILLED U.S. military servicemen. Celebrex, Bextra …

Satisfied with the content?

Continue to create your account.